Stockreport

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the...

Eterna Therapeutics Inc.  (ERNA) 
PDF Eterna reports the development of an mRNA-engineered iPSC line developed using UltraSlice™ to express a B2M-HLA-E fusion transgene in lieu of the endogenous B2M gene pro [Read more]